Intravenous dexamethasone versus oral glycerol versus placebo in reducing auditory sequelae of childhood bacterial meningitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN35932399

Enrollment

704

Registered

2006-12-28

Start date

1996-12-26

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial meningitis Nervous System Diseases Inflammatory diseases of the central nervous system

Interventions

Adjuvant medication with intravenous DXM, oral GLY, both, or neither agent. 4 arms: Arm 1: DXM + placebo (PLA) Arm 2: DXM + GLY Arm 3: GLY + PLA Arm 4: PLA + PLA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children at age two months to 16 years in whom bacterial meningitis was diagnosed and treated in the Institutions

Exclusion criteria

Exclusion criteria: 1. Recent head injury 2. Previous neurosurgery 3. Neurological diseases 4. Immunosuppression 5. Known hearing impairment 6. More than one dose of parenteral anti-microbial

Design outcomes

Primary

Measure	Time frame
1. Death 2. Severe neurological sequelae 3. Hearing impairment	—

Secondary

Measure	Time frame
Composite endpoints: 1. Severe neurological sequelae or death 2. Subanalysis on Hib meningitis with or without prior antimicrobials	—

Countries

Argentina, Brazil, Dominican Republic, Ecuador, Paraguay, Venezuela

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026